Active-ingredient Dossier
Imatinib
Active-ingredient Dossier for Imatinib (tyrosine kinase inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: GLIVEC
- Brand: IMATAB
- Brand: Imatinib-DRLA
- Brand: ZUCIEL
- Brand: ARX-IMATINIB
- Brand: GILMAT
- Therapeutic area: Oncology
What is
Imatinib Imatinib is a tyrosine kinase inhibitor.
Australian brands containing
Imatinib — GLIVEC — IMATINIB SANDOZ — ZUCIEL — TERONIB
Therapeutic areas
Imatinib is registered in oncology, with four brands containing this ingredient on the ARTG.
Sponsor landscape
Three sponsors market imatinib in Australia: Novartis Pharmaceuticals, Sandoz, and Hetero.
PBS and regulatory activity
One brand with imatinib is PBS-listed, with the latest PBS schedule date of 1 May 2026. In the 2017–18 financial year, imatinib incurred government cost of approximately $66.2 million across 25,760 scripts. The latest PBAC outcome was recorded on 1 May 2025, with three brands having PBAC outcomes on record.